We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Should You Buy, Hold or Sell Tempus AI Stock Amid AI Boom?
Read MoreHide Full Article
Key Takeaways
Tempus AI shares gained 17.9% in a month, outperforming peers amid growing demand for healthcare AI.
TEM's Data and Applications revenues rose 28% to $93.2M, supported by a 36% increase in Insights revenues.
TEM's premium valuation of 6.59X sales and reliance on regulatory approvals and reimbursement pose risks.
The artificial intelligence (AI) in healthcare market is projected to grow $39.93 billion at a CAGR of 34% from 2025 to 2030, driven by the proliferation of big data and the increasing complexity of healthcare datasets. The market is transforming clinical and operational practices as healthcare providers increasingly adopt AI to improve decision-making and operational efficiency. However, wider adoption faces challenges, including the need for robust data governance to protect patient privacy and high implementation costs. (Per Technavio).
For Tempus AI (TEM - Free Report) , these market trends create a favorable demand backdrop across its Data and Applications segment. In the second quarter, Data and Applications revenues increased 28% to $93.2 million. Insights, which includes data licensing and modeling, advanced 36% as pharmaceutical customers expanded their use of Tempus' multimodal data and AI capabilities.
TEM’s Shares Outperform Peers
TEM’s shares have gained 17.9% over the past month. During the same period, shares of key peers Claritev Corporation (CTEV - Free Report) and iRhythm Holdings (IRTC - Free Report) have declined 33.8% and 9.1%, respectively.
Image Source: Zacks Investment Research
Expanding Data Monetization
Tempus’ Data and Applications segment maintained broad-based momentum in the first half of 2026 as larger life sciences relationships expanded beyond data licensing. Tempus signed about $200 million of new Data and Applications licenses during the second quarter, including agreements with BioNTech, Daiichi Sankyo, LevelSet Bio and Incyte. It also delivered the first version of its oncology foundation model to AstraZeneca after meeting acceptance criteria.
Further strengthening its data capabilities, Tempus launched an initiative to build a multimodal whole-genome dataset, initially targeting 100,000 disease-specific whole-genome sequences paired with longitudinal clinical outcomes, with a long-term goal of reaching 1 million genomes. Together, its expanding licensing relationships, AI modeling capabilities and genomic data investments could support sustained recurring growth.
Product Innovation Expands TEM’s Portfolio
Tempus AI continues to expand its precision medicine and AI capabilities through new product launches and regulatory milestones. In August, the company received FDA 510(k) clearance for Tempus ECG-PH, an AI-enabled software device that analyzes standard 12-lead electrocardiograms for signs associated with pulmonary hypertension.
In July, it also launched OneOme pharmacogenomics testing solution nationwide to provide genetic insights for medication safety, dosing and toxicity risk assessment. In digital pathology, Tempus partnered with Yale New Haven Hospital and Memorial Sloan Kettering Cancer Center in June to launch the IMS Open-Source Consortium, which aims to develop an open-source digital pathology platform and viewer to promote standardization and broader access. Earlier, in May, Tempus introduced the next generation of Lens, its agentic AI platform designed to accelerate drug development and research.
Expensive Valuation
With a forward one-year price-to-sales (P/S) of 6.59X, TEM’s shares are trading at a premium to the industry average of 4.70X. It has a Value Score of F at present.
Image Source: Zacks Investment Research
Headwind Limiting TEM’s Growth
FDA approval for tumor-only xT CDx has reduced some reimbursement risk for Tempus, but further pricing benefits depend on regulatory approvals and payer decisions. The xT migration is expected to support reimbursement growth in 2027, while the larger xF opportunity depends on FDA approval expected in the second half of 2027 and subsequent ADLT pricing. Revenues from minimal residual disease (MRD) testing also depend on coverage for specific indications, with Personalis still in the early stages of expanding reimbursement. Therefore, much of the expected pricing benefit is yet to materialize. Delays in xF approval, ADLT pricing or broader MRD coverage could postpone revenue growth and margin improvement.
Estimates for TEM Heading North
The Zacks Consensus Estimate for TEM’s 2026 sales and loss per share implies a year-over-year improvement of 25.5% and 55.7%, respectively. The bottom-line estimates have remained unchanged in the past 60 days.
Image Source: Zacks Investment Research
Our Take
Tempus is benefiting from growing demand for AI in healthcare, strong data licensing momentum and expanding precision medicine offerings. Its growing partnerships and investments in research and development could support long-term growth. However, its continued dependence on regulatory approvals and reimbursement expansion remains a key risk.
Given the premium valuation, estimates and stock price performance, we advise investors who already hold this Zacks Rank #3 (Hold) stock to maintain their positions, while prospective investors may consider waiting for a more favorable entry point. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
View the Zacks #1 Rank List
Image: Bigstock
Should You Buy, Hold or Sell Tempus AI Stock Amid AI Boom?
Key Takeaways
The artificial intelligence (AI) in healthcare market is projected to grow $39.93 billion at a CAGR of 34% from 2025 to 2030, driven by the proliferation of big data and the increasing complexity of healthcare datasets. The market is transforming clinical and operational practices as healthcare providers increasingly adopt AI to improve decision-making and operational efficiency. However, wider adoption faces challenges, including the need for robust data governance to protect patient privacy and high implementation costs. (Per Technavio).
For Tempus AI (TEM - Free Report) , these market trends create a favorable demand backdrop across its Data and Applications segment. In the second quarter, Data and Applications revenues increased 28% to $93.2 million. Insights, which includes data licensing and modeling, advanced 36% as pharmaceutical customers expanded their use of Tempus' multimodal data and AI capabilities.
TEM’s Shares Outperform Peers
TEM’s shares have gained 17.9% over the past month. During the same period, shares of key peers Claritev Corporation (CTEV - Free Report) and iRhythm Holdings (IRTC - Free Report) have declined 33.8% and 9.1%, respectively.
Image Source: Zacks Investment Research
Expanding Data Monetization
Tempus’ Data and Applications segment maintained broad-based momentum in the first half of 2026 as larger life sciences relationships expanded beyond data licensing. Tempus signed about $200 million of new Data and Applications licenses during the second quarter, including agreements with BioNTech, Daiichi Sankyo, LevelSet Bio and Incyte. It also delivered the first version of its oncology foundation model to AstraZeneca after meeting acceptance criteria.
Further strengthening its data capabilities, Tempus launched an initiative to build a multimodal whole-genome dataset, initially targeting 100,000 disease-specific whole-genome sequences paired with longitudinal clinical outcomes, with a long-term goal of reaching 1 million genomes. Together, its expanding licensing relationships, AI modeling capabilities and genomic data investments could support sustained recurring growth.
Product Innovation Expands TEM’s Portfolio
Tempus AI continues to expand its precision medicine and AI capabilities through new product launches and regulatory milestones. In August, the company received FDA 510(k) clearance for Tempus ECG-PH, an AI-enabled software device that analyzes standard 12-lead electrocardiograms for signs associated with pulmonary hypertension.
In July, it also launched OneOme pharmacogenomics testing solution nationwide to provide genetic insights for medication safety, dosing and toxicity risk assessment. In digital pathology, Tempus partnered with Yale New Haven Hospital and Memorial Sloan Kettering Cancer Center in June to launch the IMS Open-Source Consortium, which aims to develop an open-source digital pathology platform and viewer to promote standardization and broader access. Earlier, in May, Tempus introduced the next generation of Lens, its agentic AI platform designed to accelerate drug development and research.
Expensive Valuation
With a forward one-year price-to-sales (P/S) of 6.59X, TEM’s shares are trading at a premium to the industry average of 4.70X. It has a Value Score of F at present.
Image Source: Zacks Investment Research
Headwind Limiting TEM’s Growth
FDA approval for tumor-only xT CDx has reduced some reimbursement risk for Tempus, but further pricing benefits depend on regulatory approvals and payer decisions. The xT migration is expected to support reimbursement growth in 2027, while the larger xF opportunity depends on FDA approval expected in the second half of 2027 and subsequent ADLT pricing. Revenues from minimal residual disease (MRD) testing also depend on coverage for specific indications, with Personalis still in the early stages of expanding reimbursement. Therefore, much of the expected pricing benefit is yet to materialize. Delays in xF approval, ADLT pricing or broader MRD coverage could postpone revenue growth and margin improvement.
Estimates for TEM Heading North
The Zacks Consensus Estimate for TEM’s 2026 sales and loss per share implies a year-over-year improvement of 25.5% and 55.7%, respectively. The bottom-line estimates have remained unchanged in the past 60 days.
Image Source: Zacks Investment Research
Our Take
Tempus is benefiting from growing demand for AI in healthcare, strong data licensing momentum and expanding precision medicine offerings. Its growing partnerships and investments in research and development could support long-term growth. However, its continued dependence on regulatory approvals and reimbursement expansion remains a key risk.
Given the premium valuation, estimates and stock price performance, we advise investors who already hold this Zacks Rank #3 (Hold) stock to maintain their positions, while prospective investors may consider waiting for a more favorable entry point. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.